Dual bronchodilator versus inhaled corticosteroid/long-acting β-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials.

Background: Long-acting muscarinic antagonist/long-acting β-agonist (LAMA/LABA, also known as dual bronchodilator) and inhaled corticosteroid/LABA (ICS/LABA) are the cornerstone of maintenance treatment for stable chronic obstructive pulmonary disease (COPD) patients. We aimed to comprehensively compare the efficacy and safety of the two maintenance treatment in COPD patients.

Methods: We searched the database Embase, Cochrane Library, PubMed, and Clinical Trials.